A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.
Bacterial flagellin is a potent adjuvant that enhances adaptive immune responses to a variety of protein antigens. The vaccinia virus antigens L1R and B5R are highly immunogenic in the context of the parent virus, but recombinant forms of the proteins are only weakly immunogenic. Therefore we evaluated the humoral response to these antigens in mice when flagellin was used as an adjuvant. Flagellin-L1R and flagellin-B5R fusion proteins were more potent than flagellin, L1R, and B5R as separate proteins. At least three immunizations with flagellin-L1R and flagellin-B5R fusion proteins were required to confer protection in mice against challenge with vaccinia virus. Immune mice exhibited only limited signs of disease following challenge. Additionally, virus neutralization titers correlated with protection. Depletion of complement using cobra venom factor resulted in a marked decrease in the survival of immunized mice after challenge with vaccinia virus. Our results are consistent with the conclusion that flagellin-L1R and flagellin-B5R fusion proteins are effective in eliciting protective immunity against vaccinia virus that is dependent, in large part, on complement.
Delaney
Kristen N
KN
Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.
Phipps
James P
JP
Johnson
John B
JB
Mizel
Steven B
SB
D000276:Adjuvants, Immunologic; D000818:Animals; D003165:Complement System Proteins / Q000276:immunology*; D005260:Female; D005408:Flagellin / Q000235:genetics / Q000276:immunology*; D006367:HeLa Cells; D006801:Humans; D007273:Injections, Intramuscular; D051379:Mice; D008807:Mice, Inbred BALB C; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000276:immunology; D012900:Smallpox Vaccine / Q000008:administration & dosage*; D014614:Vaccines, Synthetic / Q000008:administration & dosage; D014615:Vaccinia / Q000276:immunology / Q000517:prevention & control*; D014616:Vaccinia virus / Q000276:immunology*
D000276:Adjuvants, Immunologic; D011993:Recombinant Fusion Proteins; D012900:Smallpox Vaccine; D014614:Vaccines, Synthetic; D005408:Flagellin; D003165:Complement System Proteins